Curis stock jumps 11% on positive emavusertib trial data By Investing.com
Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.
How this was made
The 30-second read
Why it matters
Updated TakeAim Lymphoma efficacy results and increased CLL enrollment guidance are likely to drive a reassessment of clinical/regulatory probability and near-term cash burn expectations tied to trial progression.
Market read
Traders can use the specific ORR figures and the revised year-end CLL enrollment range (5 to 5-10 patients) as fresh catalysts for biotech positioning and options pricing.
What to watch
The article does not provide safety/tolerability, duration of response, progression-free survival, or interim endpoints for PCNSL/CLL, which can materially affect valuation even with higher ORR.
Background
Curis is developing emavusertib, an orally available IRAK4 and FLT3 inhibitor, in combination with BTK inhibitors across PCNSL and CLL studies.
Ticker impact
Curis shares jumped 11% after updated emavusertib TakeAim Lymphoma data showed 86% ORR in BTK inhibitor-naive PCNSL patients and raised CLL enrollment guidance.
Bullish bias for the next several sessions, with follow-through dependent on further trial updates and FDA/EMA discussions.
The article provides specific response-rate figures, patient subgroups, and a concrete year-end enrollment guidance increase, which are direct catalysts for biotech risk/reward repricing.
Market effects
Reinforces investor appetite for IRAK4/FLT3 inhibitor strategies in lymphoma/CLL combinations, potentially lifting sentiment for similar clinical-stage oncology names.
Limited, primarily US small-cap biotech sentiment.
Moderate, as FDA/EMA guidance context is referenced but no cross-border regulatory decision is reported.
Counterpoint
Response rates may not translate into durable outcomes or accelerated-approval eligibility; small sample sizes and subgroup imbalance can exaggerate early efficacy.
Key entities
- companyCuris, Inc.
NASDAQ-listed biotech whose emavusertib trial updates drove an 11% stock move.
- drug_candidateEmavusertib
Orally available IRAK4 and FLT3 inhibitor being tested with BTK inhibitors in PCNSL and CLL.
- regulatorsFDA and EMA
Meetings completed in 2025 with guidance suggesting the ongoing study could support accelerated approval in Relapsed/Refractory PCNSL.
